Literature DB >> 8055233

Clostridium difficile diarrhea: pathogenesis, epidemiology, and treatment.

R D Mitty1, J T LaMont.   

Abstract

Clostridium difficile, the bacterium responsible for antibiotic-associated diarrhea and colitis, has become a significant cause of morbidity and prolonged hospital stays, largely because of the increasing use of broad-spectrum antibiotics. This gram-positive organism, which can lay dormant in its spore form in the environment for extended periods of time, proliferates in the colon when the normal colonic flora is compromised by antibiotic use. C. difficile produces intestinal inflammation and diarrhea through the elaboration of two protein exotoxins, toxin A and toxin B. The spectrum of clinical manifestations ranges from mild diarrhea that resolves with the cessation of the offending antibiotic, to fulminant pseudomembranous colitis complicated by megacolon and perforation. Our ability to meet the challenge offered by this organism has been enhanced by the development of new diagnostic modalities as well as the development of new therapeutic regimens. Through further investigation of the structure and function of toxins A and B and further study of the interaction of C. difficile with the normal colonic flora, advances will continue to be made in the prevention and treatment of antibiotic-associated colitis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8055233

Source DB:  PubMed          Journal:  Gastroenterologist        ISSN: 1065-2477


  7 in total

1.  Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection.

Authors:  April Roberts; Joanna McGlashan; Ibrahim Al-Abdulla; Roger Ling; Harriet Denton; Steve Green; Ruth Coxon; John Landon; Clifford Shone
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

2.  A new role for heat shock factor 27 in the pathophysiology of Clostridium difficile toxin B.

Authors:  Murali K Yanda; William B Guggino; Liudmila Cebotaru
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-11-11       Impact factor: 4.052

3.  Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain.

Authors:  E T Ryan; J R Butterton; R N Smith; P A Carroll; T I Crean; S B Calderwood
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

4.  C. difficile colitis--predictors of fatal outcome.

Authors:  Haig Dudukgian; Ester Sie; Claudia Gonzalez-Ruiz; David A Etzioni; Andreas M Kaiser
Journal:  J Gastrointest Surg       Date:  2010-02       Impact factor: 3.452

Review 5.  Neutrophil-mediated inflammation in the pathogenesis of Clostridium difficile infections.

Authors:  Shinsmon Jose; Rajat Madan
Journal:  Anaerobe       Date:  2016-04-05       Impact factor: 3.331

6.  Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters.

Authors:  P J Giannasca; Z X Zhang; W D Lei; J A Boden; M A Giel; T P Monath; W D Thomas
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

7.  Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.

Authors:  Michael Maynard-Smith; Helen Ahern; Joanna McGlashan; Philip Nugent; Roger Ling; Harriet Denton; Ruth Coxon; John Landon; April Roberts; Clifford Shone
Journal:  Vaccine       Date:  2013-12-14       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.